| 000 | 01741 a2200481 4500 | ||
|---|---|---|---|
| 005 | 20250517115446.0 | ||
| 264 | 0 | _c20180221 | |
| 008 | 201802s 0 0 eng d | ||
| 022 | _a1949-2553 | ||
| 024 | 7 |
_a10.18632/oncotarget.12132 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aBodo, Juraj | |
| 245 | 0 | 0 |
_aAcquired resistance to venetoclax (ABT-199) in t(14;18) positive lymphoma cells. _h[electronic resource] |
| 260 |
_bOncotarget _cOct 2016 |
||
| 300 |
_a70000-70010 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article | ||
| 650 | 0 | 4 | _aAnimals |
| 650 | 0 | 4 |
_aApoptosis _xdrug effects |
| 650 | 0 | 4 |
_aAutophagy _xdrug effects |
| 650 | 0 | 4 |
_aBcl-2-Like Protein 11 _xanalysis |
| 650 | 0 | 4 |
_aBridged Bicyclo Compounds, Heterocyclic _xtherapeutic use |
| 650 | 0 | 4 |
_aCell Proliferation _xdrug effects |
| 650 | 0 | 4 | _aChromosomes, Human, Pair 14 |
| 650 | 0 | 4 | _aChromosomes, Human, Pair 18 |
| 650 | 0 | 4 | _aDrug Resistance, Neoplasm |
| 650 | 0 | 4 |
_aExtracellular Signal-Regulated MAP Kinases _xantagonists & inhibitors |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aLymphoma, Follicular _xdrug therapy |
| 650 | 0 | 4 | _aMice |
| 650 | 0 | 4 | _aPhosphoinositide-3 Kinase Inhibitors |
| 650 | 0 | 4 |
_aProto-Oncogene Proteins c-akt _xantagonists & inhibitors |
| 650 | 0 | 4 |
_aProto-Oncogene Proteins c-bcl-2 _xanalysis |
| 650 | 0 | 4 |
_aSulfonamides _xtherapeutic use |
| 650 | 0 | 4 | _aTranslocation, Genetic |
| 700 | 1 | _aZhao, Xiaoxian | |
| 700 | 1 | _aDurkin, Lisa | |
| 700 | 1 | _aSouers, Andrew J | |
| 700 | 1 | _aPhillips, Darren C | |
| 700 | 1 | _aSmith, Mitchell R | |
| 700 | 1 | _aHsi, Eric D | |
| 773 | 0 |
_tOncotarget _gvol. 7 _gno. 43 _gp. 70000-70010 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.18632/oncotarget.12132 _zAvailable from publisher's website |
| 999 |
_c26447348 _d26447348 |
||